GBIO is expected to report earnings to fall 11.97% to -27 cents per share on November 07
Q3'24
Est.
$-0.27
Q2'24
Missed
by $0.04
Q1'24
Missed
by $0.72
Q4'23
Missed
by $0.07
Q3'23
Beat
by $0.06
The last earnings report on August 07 showed earnings per share of -31 cents, missing the estimate of -27 cents. With 152.06K shares outstanding, the current market capitalization sits at 162.18M.
a genetic medicines company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases